CenterBook Partners LP Sells 359,867 Shares of Liquidia Corporation $LQDA

CenterBook Partners LP reduced its position in shares of Liquidia Corporation (NASDAQ:LQDA) by 74.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 124,982 shares of the company’s stock after selling 359,867 shares during the period. CenterBook Partners LP’s holdings in Liquidia were worth $4,311,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after acquiring an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after acquiring an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Liquidia by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after acquiring an additional 16,022 shares during the last quarter. Creative Planning raised its stake in shares of Liquidia by 40.7% in the second quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after acquiring an additional 7,765 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Liquidia by 13.4% in the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after acquiring an additional 11,111 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LQDA has been the subject of a number of research analyst reports. BTIG Research boosted their target price on shares of Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Lifesci Capital raised shares of Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Finally, Wells Fargo & Company boosted their target price on shares of Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $55.63.

Liquidia Trading Up 3.3%

LQDA opened at $63.90 on Tuesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The company has a market cap of $5.68 billion, a price-to-earnings ratio of 456.46 and a beta of 0.57. The firm has a 50 day simple moving average of $47.32 and a 200 day simple moving average of $39.87. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $66.78.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The business had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm’s revenue for the quarter was up 4187.1% on a year-over-year basis. On average, sell-side analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current year.

Insider Buying and Selling at Liquidia

In related news, CEO Roger Jeffs sold 6,428 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $62.18, for a total transaction of $399,693.04. Following the completion of the transaction, the chief executive officer owned 1,041,667 shares in the company, valued at approximately $64,770,854.06. The trade was a 0.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Paul B. Manning sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $63.91, for a total transaction of $12,782,000.00. Following the transaction, the director owned 716,311 shares of the company’s stock, valued at approximately $45,779,436.01. This represents a 21.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,448,711 shares of company stock valued at $71,404,763 over the last 90 days. Company insiders own 25.60% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).